Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Sells $67,389.22 in Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Verneuil Vanina De sold 7,373 shares of Vir Biotechnology stock in a transaction dated Wednesday, February 26th. The stock was sold at an average price of $9.14, for a total value of $67,389.22. Following the completion of the sale, the executive vice president now owns 79,460 shares of the company’s stock, valued at approximately $726,264.40. The trade was a 8.49 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Verneuil Vanina De also recently made the following trade(s):

• On Monday, December 2nd, Verneuil Vanina De sold 76 shares of Vir Biotechnology stock. The stock was sold at an average price of $8.22, for a total value of $624.72.

Vir Biotechnology Price Performance

NASDAQ:VIR opened at $8.39 on Friday. Vir Biotechnology, Inc. has a fifty-two week low of $6.56 and a fifty-two week high of $14.45. The stock has a market capitalization of $1.16 billion, a PE ratio of -2.14 and a beta of 0.63. The business’s 50-day simple moving average is $9.46 and its 200-day simple moving average is $8.49.

Vir Biotechnology (NASDAQ:VIR) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($0.76) earnings per share for the quarter, beating the consensus estimate of ($0.85) by $0.09. Vir Biotechnology had a negative return on equity of 36.71% and a negative net margin of 678.40%. The business had revenue of $12.37 million for the quarter, compared to analysts’ expectations of $8.14 million. On average, research analysts expect that Vir Biotechnology, Inc. will post -3.92 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on VIR shares. Leerink Partners raised their target price on Vir Biotechnology from $18.00 to $20.00 and gave the stock an “outperform” rating in a report on Monday, January 13th. JPMorgan Chase & Co. raised their target price on Vir Biotechnology from $10.00 to $14.00 and gave the stock a “neutral” rating in a report on Thursday, January 9th. HC Wainwright restated a “buy” rating and set a $110.00 target price on shares of Vir Biotechnology in a report on Friday. Needham & Company LLC restated a “buy” rating and set a $19.00 target price on shares of Vir Biotechnology in a report on Thursday. Finally, Barclays raised their target price on Vir Biotechnology from $26.00 to $31.00 and gave the stock an “overweight” rating in a report on Friday. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $35.67.

Hedge Funds Weigh In On Vir Biotechnology

Several institutional investors have recently modified their holdings of the business. State Street Corp lifted its holdings in shares of Vir Biotechnology by 10.4% during the 3rd quarter. State Street Corp now owns 5,625,533 shares of the company’s stock valued at $42,135,000 after purchasing an additional 530,645 shares in the last quarter. Geode Capital Management LLC lifted its stake in Vir Biotechnology by 0.4% in the 4th quarter. Geode Capital Management LLC now owns 2,196,601 shares of the company’s stock valued at $16,127,000 after acquiring an additional 7,827 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in Vir Biotechnology by 58.0% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,915,465 shares of the company’s stock valued at $14,059,000 after acquiring an additional 703,360 shares in the last quarter. Millennium Management LLC lifted its stake in Vir Biotechnology by 55.3% in the 4th quarter. Millennium Management LLC now owns 1,715,083 shares of the company’s stock valued at $12,589,000 after acquiring an additional 610,367 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in Vir Biotechnology by 10.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,252,655 shares of the company’s stock valued at $9,194,000 after acquiring an additional 118,379 shares in the last quarter. Institutional investors own 65.32% of the company’s stock.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).